Nanovector s.r.l, Torino, Italy.
Prog Brain Res. 2009;180:181-92. doi: 10.1016/S0079-6123(08)80010-6. Epub 2009 Dec 8.
The chapter examined solid lipid nanoparticles (SLN) and microemulsions, chosen as carriers of drugs, administered in vivo to be transported to the central nervous system. Drugs of different structures and for different therapies have been studied such as doxorubicin SLN stealth and nonstealth administered in rats by intravenous route, apomorphine SLN administered in rats by duodenal route, melatonin SLN administered by transdermal and oral routes in humans, and apomorphine microemulsion administered by transdermal route in Parkinson's patients. The pharmacokinetics of the drug, followed in most studies, put in evidence that the many important pharmacokinetic parameters were notably improved versus the drug alone or in a commercial formulation.
本章考察了固体脂质纳米粒(SLN)和微乳,它们被选择作为药物载体,通过体内给药来输送到中枢神经系统。研究了不同结构和不同治疗用途的药物,例如多柔比星 SLN 隐形和非隐形,通过静脉途径给予大鼠;阿扑吗啡 SLN,通过十二指肠途径给予大鼠;褪黑素 SLN,通过经皮和口服途径给予人体;阿扑吗啡微乳,通过经皮途径给予帕金森病患者。在大多数研究中,药物的药代动力学研究表明,与单独使用药物或使用商业制剂相比,许多重要的药代动力学参数都得到了显著改善。